|
Market Cap (5-Jun) $111,926,056 (1,449th) |
Close (30-Jun) $0.075 |
Volume (30-Jun) 0 |
Shortsold (11-Oct) 108,089 (0.02%) (492nd) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.02 |
PAA released this announcement to the ASX on 7 July 2021, 8:22. The announcement is not marked as price sensitive, and is 1 page(s) in length and 388.35kb in size.
You can view all announcements from PAA and see how they appear on a price chart on the announcements page.
At the date of this announcement, PAA was 0.072% short sold according to ASIC data. It was ranked the 487th most shorted stock on the ASX. It remains ranked 492nd as of the latest reported data (11 October 2024).
| Other Recent Announcements from PAA | |
|---|---|
| Results of General Meeting | 30 June 2023, 12:38 |
| Trading Halt | 30 June 2023, 9:48 |
| General Meeting - Chairman Script | 30 June 2023, 9:42 |
| PharmAust establishes monepantel GMP tablet stability | 7 July 2021, 8:22 |
| Phase IIb Dog Trial Achieves Interim Clinical Endpoints | 28 June 2021, 8:29 |
| PharmAust receives ethics approval for Phase I trial in MND | 2 June 2021, 8:23 |
| Dr Kim Agnew appointed Principal Investigator of dog trial | 14 May 2021, 11:13 |
You must be logged in to post a reply.
PharmAust 